Neko Health raises $700 million to expand AI body scans in the US

Neko Health has secured $700 million in funding to roll out its AI-driven body scans across the United States, kicking off with a flagship clinic in New York. This preventive screening platform integrates medical imaging, blood analysis, proprietary sensors, and expert clinician review.

Lightspeed Venture Partners led the Series C round, co-led by O.G. Venture Partners. The funding also included participation from existing investors Atomico, General Catalyst, and Lakestar, as well as new backers Liberty City Ventures, Positive Sum, and BDT & MSD.

David Ofer from O.G. Venture Partners is set to join Neko’s board, pending regulatory approval.

This latest investment pushes Neko’s total disclosed funding since 2023 past $1 billion. The company previously raised $65 million in a Series A round in 2023, followed by $260 million in January 2025.

Notable individual investors in this round include Meta CEO Mark Zuckerberg and Priscilla Chan, former tennis star Maria Sharapova, musician will.i.am, and ex-footballer Thierry Henry. Existing individual backers include Reddit co-founder Alexis Ohanian and actress Zoë Saldaña.

Understanding Neko Health’s AI body scans

Neko’s clinics integrate full-body imaging, blood tests, artificial intelligence, and custom medical hardware. The service screens for early indicators of conditions such as skin cancer, cardiovascular disease, and diabetes.

The company describes the process as a 60-minute, non-invasive, and radiation-free health assessment. It utilizes proprietary sensors and blood analysis to evaluate skin conditions, blood abnormalities, pre-diabetes markers, and risk factors for metabolic syndrome, stroke, and heart attacks.

The scan also features an electrocardiogram, arterial measurements, body-composition analysis, and over 2,000 high-resolution images to map skin health. Blood samples are processed on-site, enabling results to be reviewed during the same visit.

Results are discussed in person with a medical professional.

Many metrics, including blood pressure, glucose, cholesterol, ECG data, and skin assessments, are accessible through standard healthcare. Neko’s model consolidates these with proprietary imaging, automated data collection, on-site blood processing, and clinician consultation into a single appointment.

Public clinical materials reviewed for this article do not include a comparative study demonstrating whether this integrated approach improves clinical outcomes or cost-effectiveness compared to established preventive-care pathways.

Neko stated that the funding will support clinics in New York and other US cities. Specific additional locations and a detailed expansion schedule have not yet been announced.

A waitlist for the New York clinic is available on the company’s website. Neko has not yet disclosed pricing for its US scans.

The company currently operates eight clinics across the UK and Sweden, including two in Stockholm, one each in Manchester and Birmingham, and four in London: Marylebone, Spitalfields, Covent Garden, and Victoria.

A scan costs £299 in the UK and 2,750 Swedish kronor in Sweden, roughly equivalent to $400 and $285 respectively.

Neko reported completing 100,000 scans since its 2023 launch. Over 350,000 people have registered for a scan or joined its waitlists.

According to the company, 75% of customers book and prepay for a follow-up scan at the end of their appointment.

This repeat-booking model allows clinicians to track changes in measurements and skin images over time. Public information reviewed for this article does not establish whether annual screening is appropriate for every age or risk group.

Founded in 2018 by Spotify co-founder Daniel Ek and CEO Hjalmar Nilsonne, Neko operated largely out of the public eye until launching its service in 2023.

Nilsonne noted that part of the new capital will fund further research and development into preventive screening technology.

Neko recently added body-composition measurements and clinician reviews of wearable-device data across its clinics. It has also introduced updated versions of its Derma, Echo, and Spectrum medical devices, which collect data on skin, heart function, and circulation.

The company stated that the newer equipment captures a larger volume of health data and automates more parts of the scanning process. Deployment across its clinics is planned for the coming months.

The clinic-based model requires proprietary equipment, blood-processing capacity, medical personnel, and specialist review for certain findings. Neko said its seven-room Covent Garden clinic was designed to support tens of thousands of scans annually, but capacity and staffing figures for planned US locations remain undisclosed.

US regulation and access

FDA records indicate that two of Neko’s internally developed devices received clearance via the 510(k) pathway in May 2026. Derma-2 was cleared as an adjunctive telethermographic system, while Spectrum-2 was cleared as a tissue-saturation oximeter for cardiovascular measurements.

These clearances apply to the specific devices and their intended uses, not to the complete Neko Health Scan as a single FDA-approved screening service.

Neko describes its US clinics as preventive health and wellness providers rather than full-service medical practices. Its privacy notice advises customers to continue seeing their existing clinicians for diagnoses and treatment, including for conditions identified through a Neko scan.

The company says specialist clinicians, including dermatologists and cardiologists, review findings requiring further examination. Follow-up appointments, referral letters, and introductions to outside specialists are included when recommended by a Neko clinician.

Neko’s US clinics do not currently participate in health insurance plans, and most services are not covered by payers. Customers are expected to pay directly for the initial assessment.

The company has not disclosed costs for diagnostic tests or treatment delivered by external healthcare providers. It has also not announced US pricing or whether employers, insurers, or other organizations will subsidize access.

Questions over clinical evidence

Publicly available information reviewed for this article does not include a completed peer-reviewed study validating the full screening service. A study registered on ClinicalTrials.gov is evaluating the suitability of Neko’s multimodal skin-imaging technology for screening and diagnostic support, including skin cancer and Raynaud’s phenomenon.

The trial remains an ongoing evaluation and does not establish the clinical performance of the complete Neko Health Scan.

Neko’s public materials reviewed for this article do not disclose the frequency of false-positive findings, the number of customers undergoing additional procedures, or how many flagged abnormalities are later deemed clinically unimportant.

The company’s US privacy notice identifies an AI dictation system used to summarize medical records, questionnaires, scan data, and clinical conversations, and to draft reports. Neko states that clinicians review reports produced using this system.

Public information does not provide a complete breakdown of which scan measurements or classifications rely on AI, conventional software, or direct clinical assessment. It also does not state that AI independently diagnoses the conditions covered by the service.

The FDA clearances for individual devices do not establish the performance of every algorithm used to combine or interpret the resulting data. Public materials reviewed for this article do not include detailed real-world performance figures for each AI system used in the screening process.

Neko’s reported health-outcome data is based on 1,469 customers who completed a second scan approximately one year after their first. The company said the group recorded improvements in blood pressure, cholesterol, and blood sugar, while body weight remained broadly stable.

The scans in the analysis were conducted at Neko’s Stockholm clinics. The company divided the results into a general group, a healthy group, and groups covering customers with hypertension, pre-diabetes, or diabetes.

Neko stated the analysis was not a scientific study and did not include a control group. Customers could have started treatment or changed their behavior between appointments, so the figures do not establish that the scans caused the reported improvements.

The analysis only covered customers who returned for a second privately purchased scan. Neko did not publish demographic information showing how that group compares with its wider customer base or the general population.

The company did not disclose its valuation following the latest round. The Financial Times, citing unnamed sources, reported that Neko is now valued at approximately $7 billion.

See also: NHS AI blood test could reduce invasive womb cancer checks

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events, click here for more information.

AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.